Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin

Abstract Lonidamine (LND), a metabolic modulator, sensitizes DB-1 human melanoma to doxorubicin (DOX) chemotherapy by acidifying and de-energizing the tumor. This report compares the effects of LND on two human melanoma lines, DB-1 and WM983B, which exhibit different metabolic properties. Using liqu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kavindra Nath, Jeffrey Roman, David S. Nelson, Lili Guo, Seung-Cheol Lee, Stepan Orlovskiy, Kevin Muriuki, Daniel F. Heitjan, Stephen Pickup, Dennis B. Leeper, Ian A. Blair, Mary E. Putt, Jerry D. Glickson
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Lonidamine (LND) Growth Delay Seahorse Tumor Lactate Levels Extracellular Acidification Rate (ECAR) Medicine R Science Q
Acceso en línea:	https://doaj.org/article/0e896a59367143cd9eaf61fe48cf3d20
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin

Ejemplares similares